Roivant Sciences November 2023 Overview Presentation

Roivant Sciences November 2023 investor overview covering the company's development of transformative medicines, including the pending sale of Telavant to Roche, recent Phase 3 trial results for ADORING 1 and ADORING 2, and Phase 1 data for IMVT-1402. The company maintains a strong cash position of $1.4B with additional proceeds expected from strategic transactions.